CO6721010A2 - Antagonistas de mdm2 de espiro-oxindol - Google Patents
Antagonistas de mdm2 de espiro-oxindolInfo
- Publication number
- CO6721010A2 CO6721010A2 CO13140762A CO13140762A CO6721010A2 CO 6721010 A2 CO6721010 A2 CO 6721010A2 CO 13140762 A CO13140762 A CO 13140762A CO 13140762 A CO13140762 A CO 13140762A CO 6721010 A2 CO6721010 A2 CO 6721010A2
- Authority
- CO
- Colombia
- Prior art keywords
- spiro
- oxindole
- mdm2 antagonists
- mdm2
- antagonists
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41309410P | 2010-11-12 | 2010-11-12 | |
| US201161451958P | 2011-03-11 | 2011-03-11 | |
| US201161451968P | 2011-03-11 | 2011-03-11 | |
| US201161470992P | 2011-04-01 | 2011-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6721010A2 true CO6721010A2 (es) | 2013-07-31 |
Family
ID=46048358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13140762A CO6721010A2 (es) | 2010-11-12 | 2013-06-12 | Antagonistas de mdm2 de espiro-oxindol |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8680132B2 (enExample) |
| EP (1) | EP2638046A4 (enExample) |
| JP (1) | JP2014500870A (enExample) |
| KR (1) | KR101929188B1 (enExample) |
| CN (1) | CN103298818B (enExample) |
| AR (1) | AR083849A1 (enExample) |
| AU (1) | AU2011326395B2 (enExample) |
| CA (1) | CA2817585A1 (enExample) |
| CO (1) | CO6721010A2 (enExample) |
| CR (1) | CR20130271A (enExample) |
| DO (1) | DOP2013000104A (enExample) |
| EA (1) | EA201390682A1 (enExample) |
| EC (1) | ECSP13012678A (enExample) |
| GT (1) | GT201300118A (enExample) |
| IL (1) | IL226275A0 (enExample) |
| MA (1) | MA34732B1 (enExample) |
| MX (1) | MX2013005238A (enExample) |
| NI (1) | NI201300041A (enExample) |
| NZ (1) | NZ611866A (enExample) |
| PE (1) | PE20140408A1 (enExample) |
| PH (1) | PH12013500955A1 (enExample) |
| SG (1) | SG190230A1 (enExample) |
| TW (1) | TWI535723B (enExample) |
| UA (1) | UA109464C2 (enExample) |
| UY (1) | UY33725A (enExample) |
| WO (1) | WO2012065022A2 (enExample) |
| ZA (1) | ZA201304042B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
| RU2553269C2 (ru) | 2009-11-12 | 2015-06-10 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| PL2603600T3 (pl) | 2010-08-13 | 2019-06-28 | Aileron Therapeutics, Inc. | Makrocykle peptidomometyczne |
| TR201807311T4 (tr) | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
| CA2852468A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
| MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| EP2752191A1 (en) * | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| EP3004109A1 (en) | 2013-05-27 | 2016-04-13 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| EA028035B1 (ru) | 2013-05-28 | 2017-09-29 | Новартис Аг | Производные пиразолопирролидин-4-она и их применение при лечении заболевания |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| WO2015075665A1 (en) | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
| IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
| CN106794171B (zh) | 2014-04-17 | 2020-03-24 | 密歇根大学董事会 | Mdm2抑制剂和使用其的治疗方法 |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| WO2016028391A2 (en) | 2014-08-18 | 2016-02-25 | Hudson Biopharma Inc. | Spiropyrrolidines as mdm2 inhibitors |
| EA038071B1 (ru) | 2014-08-21 | 2021-07-01 | Бёрингер Ингельхайм Интернациональ Гмбх | СОЕДИНЕНИЕ СПИРО[3H-ИНДОЛ-3,2'-ПИРРОЛИДИН]-2(1H)-ОНА И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MDM2-p53 |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
| MX377009B (es) | 2015-10-09 | 2025-03-07 | Boehringer Ingelheim Int | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. |
| CN105693738A (zh) * | 2016-01-14 | 2016-06-22 | 绍兴文理学院 | 3’-苯基螺[吲哚啉-3,2’-吡咯烷]-2-酮类衍生物及其制备方法和应用 |
| JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| JP7001614B2 (ja) | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| CN107652296B (zh) * | 2016-07-26 | 2020-08-04 | 南开大学 | 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 |
| JP6848047B2 (ja) | 2016-08-08 | 2021-03-24 | フェイ シアオ， | スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用 |
| WO2018092020A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| US9822128B1 (en) | 2017-06-01 | 2017-11-21 | King Saud University | Substituted spirooxindoles |
| CA3087110A1 (en) * | 2017-12-29 | 2019-07-04 | Gan & Lee Pharmaceuticals | Compounds capable of being used as tumor inhibitor, preparation method thereof, and application thereof |
| CN109988070B (zh) * | 2017-12-29 | 2022-07-26 | 南京富润凯德生物医药有限公司 | 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用 |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| BR112021006647A2 (pt) | 2018-10-08 | 2021-07-13 | The Regents Of The University Of Michigan | degradores de proteína mdm2 de pequenas moléculas |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| CA3202764A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US20250073340A1 (en) * | 2021-01-23 | 2025-03-06 | Newave Pharmaceutical Inc. | Spirocyclic mdm2 modulator and uses thereof |
| CN112876488B (zh) * | 2021-02-18 | 2021-12-21 | 苏州大学 | 螺环吲哚啉衍生物及其制备方法和应用 |
| EP4294513A1 (en) | 2021-02-19 | 2023-12-27 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| CN115215872A (zh) * | 2021-04-15 | 2022-10-21 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物 |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| US12398147B2 (en) | 2021-05-11 | 2025-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US12145941B2 (en) | 2021-12-08 | 2024-11-19 | Enanta Pharmaceuticals, Inc. | Heterocyclic antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| CN116283701B (zh) * | 2021-12-21 | 2025-04-22 | 中国科学院上海药物研究所 | 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物 |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN118047784B (zh) * | 2022-10-13 | 2025-09-16 | 中国科学院上海药物研究所 | 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219661A (en) | 1962-12-14 | 1965-11-23 | Warner Lambert Pharmaceutical | Spirooxindole and spirodehydroindole alkaloids and process therefor |
| GB1056537A (en) | 1963-07-16 | 1967-01-25 | Smith Kline French Lab | Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| RU2084449C1 (ru) | 1994-03-02 | 1997-07-20 | Всероссийский научный центр по безопасности биологически активных веществ | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью |
| US5773455A (en) | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| DE59814452D1 (de) | 1997-01-20 | 2010-06-24 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| WO1999012904A1 (en) | 1997-09-08 | 1999-03-18 | Arqule, Inc. | Spiro[pyrrolidine-2,3'-oxindole] compounds and methods of use |
| EP1109020B1 (en) | 1998-08-20 | 2008-12-24 | Chugai Seiyaku Kabushiki Kaisha | Method for screening candidate compounds for antitumor drug |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| US6831155B2 (en) | 1999-12-08 | 2004-12-14 | President And Fellows Of Harvard College | Inhibition of p53 degradation |
| CN1182083C (zh) | 2001-10-08 | 2004-12-29 | 廖宜芳 | 一种杀虫灭菌的配位肥及其制造方法 |
| ES2307822T3 (es) | 2001-12-18 | 2008-12-01 | F. Hoffmann-La Roche Ag | Cis-imidazolinas como inhibidores de mdm2. |
| AU2002366278B2 (en) | 2001-12-18 | 2007-07-19 | F. Hoffmann-La Roche Ag | CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors |
| JP4023184B2 (ja) | 2002-03-11 | 2007-12-19 | 昭和電工株式会社 | 発光体粒子及びその製造方法並びにその用途 |
| US7514579B2 (en) | 2002-06-13 | 2009-04-07 | Johns Hopkins University | Boronic chalcone derivatives and uses thereof |
| WO2004043371A2 (en) | 2002-11-08 | 2004-05-27 | Irm Llc | Methods and compositions for modulating p53 transcription factor |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| US7498336B2 (en) | 2003-02-13 | 2009-03-03 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Deazaflavin compounds and methods of use thereof |
| US6916833B2 (en) | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| WO2005046575A2 (en) | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| WO2005063774A1 (en) | 2003-12-22 | 2005-07-14 | Johns Hopkins University | Boronic acid aryl analogs |
| US8598127B2 (en) | 2004-04-06 | 2013-12-03 | Korea Research Institute Of Bioscience & Biotechnology | Peptides for inhibiting MDM2 function |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| JP4814228B2 (ja) | 2004-05-18 | 2011-11-16 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ｃｉｓ−イミダゾリン |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| NZ553646A (en) | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| EP1856123B1 (en) * | 2005-02-22 | 2016-02-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| SG176463A1 (en) | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| UA90145C2 (ru) | 2005-05-24 | 2010-04-12 | Лаборатуар Сероно С.А. | Трициклические спиро-производные как модуляторы crth2 |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| CA2644643C (en) | 2006-03-22 | 2015-05-19 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| WO2008036168A2 (en) * | 2006-08-30 | 2008-03-27 | The Regents Of The University Of Michigan | New small molecule inhibitors of mdm2 and the uses thereof |
| US7737174B2 (en) * | 2006-08-30 | 2010-06-15 | The Regents Of The University Of Michigan | Indole inhibitors of MDM2 and the uses thereof |
| AU2007299130A1 (en) | 2006-09-21 | 2008-03-27 | F. Hoffmann-La Roche Ag | Oxindole derivatives as anticancer agents |
| US7638548B2 (en) | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2008072655A1 (ja) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾチアゾール誘導体 |
| WO2008106507A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| BRPI0810082A2 (pt) | 2007-03-29 | 2014-10-21 | Novartis Ag | 3-imidazolil-indóis para o tratamento de doenças proliferativas |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7553833B2 (en) | 2007-05-17 | 2009-06-30 | Hoffmann-La Roche Inc. | 3,3-spiroindolinone derivatives |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| JP5438008B2 (ja) | 2007-09-21 | 2014-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| CZ301561B6 (cs) | 2007-12-04 | 2010-04-14 | Výzkumný ústav živocišné výroby, v. v. i. | Prostredek pro prevenci a potlacování kokcidióz |
| US8134001B2 (en) | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US7723372B2 (en) | 2008-03-19 | 2010-05-25 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US7928233B2 (en) | 2009-02-10 | 2011-04-19 | Hoffmann-La Roche Inc. | Spiroindolinone pyridine derivatives |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| RU2553269C2 (ru) * | 2009-11-12 | 2015-06-10 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Спирооксиндольные антагонисты mdm2 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| WO2011106650A2 (en) | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| RU2012147597A (ru) * | 2010-04-09 | 2014-05-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120046306A1 (en) | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| US20120071499A1 (en) | 2010-09-20 | 2012-03-22 | Xin-Jie Chu | Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones |
| JP2014513699A (ja) | 2011-05-11 | 2014-06-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | スピロ−オキシインドールｍｄｍ２アンタゴニスト |
-
2011
- 2011-11-11 JP JP2013538923A patent/JP2014500870A/ja not_active Ceased
- 2011-11-11 UA UAA201307447A patent/UA109464C2/uk unknown
- 2011-11-11 EA EA201390682A patent/EA201390682A1/ru unknown
- 2011-11-11 NZ NZ61186611A patent/NZ611866A/en not_active IP Right Cessation
- 2011-11-11 US US13/294,315 patent/US8680132B2/en not_active Expired - Fee Related
- 2011-11-11 EP EP11840490.4A patent/EP2638046A4/en not_active Withdrawn
- 2011-11-11 TW TW100141225A patent/TWI535723B/zh not_active IP Right Cessation
- 2011-11-11 AU AU2011326395A patent/AU2011326395B2/en not_active Ceased
- 2011-11-11 SG SG2013035894A patent/SG190230A1/en unknown
- 2011-11-11 CA CA2817585A patent/CA2817585A1/en not_active Abandoned
- 2011-11-11 PH PH1/2013/500955A patent/PH12013500955A1/en unknown
- 2011-11-11 MX MX2013005238A patent/MX2013005238A/es active IP Right Grant
- 2011-11-11 UY UY0001033725A patent/UY33725A/es not_active Application Discontinuation
- 2011-11-11 WO PCT/US2011/060300 patent/WO2012065022A2/en not_active Ceased
- 2011-11-11 CN CN201180064853.6A patent/CN103298818B/zh not_active Expired - Fee Related
- 2011-11-11 KR KR1020137015168A patent/KR101929188B1/ko not_active Expired - Fee Related
- 2011-11-11 PE PE2013001063A patent/PE20140408A1/es not_active Application Discontinuation
- 2011-11-11 AR ARP110104223A patent/AR083849A1/es unknown
-
2013
- 2013-05-09 IL IL226275A patent/IL226275A0/en unknown
- 2013-05-09 GT GT201300118A patent/GT201300118A/es unknown
- 2013-05-09 NI NI201300041A patent/NI201300041A/es unknown
- 2013-05-10 DO DO2013000104A patent/DOP2013000104A/es unknown
- 2013-06-02 EC ECSP13012678 patent/ECSP13012678A/es unknown
- 2013-06-03 ZA ZA2013/04042A patent/ZA201304042B/en unknown
- 2013-06-07 CR CR20130271A patent/CR20130271A/es unknown
- 2013-06-10 MA MA36005A patent/MA34732B1/fr unknown
- 2013-06-12 CO CO13140762A patent/CO6721010A2/es unknown
-
2014
- 2014-01-31 US US14/170,101 patent/US9302120B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6721010A2 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CO6501131A2 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| GT201200334A (es) | Morfolinopirimidinas y su uso en terapia | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| CR20130313A (es) | Anticuerpos anti-cd38 | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| GT201200321A (es) | Derivados de heteroaril imidazolona como inhibidores de jak | |
| GT201500069A (es) | Piridinonas bicìclicas novedosas | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| UY34356A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| GT201500143A (es) | Composiciones que comprenden vortioxetina y donepezilo campo tecnico | |
| ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
| CU20100248A7 (es) | Compuestos de piridina | |
| TN2013000202A1 (en) | Spiro-oxindole mdm2 antagonists | |
| CU20120052A7 (es) | Derivados de pirazol que modulan estearoil-coa-desaturasa | |
| CL2011002437A1 (es) | Compuestos derivados de quinoxalina; composicion farmaceutica que los comprende; proceso de preparacion de la composicion y su uso en el tratamiento de trastornos tumoraales. pct fase nacional. |